In this application, we propose to elucidate the molecular mechanisms by which ATM suppresses oncogenic translocations in developing lymphocytes. Specifically, we will generate novel mouse models expressing mutated ATM protein (rather than loss ATM), identify and characterize genetic lesions that synergize with ATM mutation in lymphomagenesis, and identify agents that can preferentially target ATM-mutated cancer cells for therapy. Lymphoid malignancies are characterized by recurrent chromosome translocations that result from aberrant repair of DNA double-strand breaks that normally occur during lymphocyte development. The ATM kinase is a master regulator of the DNA damage responses and a tumor suppresser gene. Germline inactivation of ATM causes Ataxia-Telangiectasia (A-T) syndrome, a neurological disorder associated with primary immunodeficiency and greatly increased risk for lymphomas and leukemia. Somatic mutations of ATM have also been identified in a broad spectrum of human cancers including >50% of mantle cell lymphomas and nearly all T-cell prolymphocytic leukemia. Our preliminary study suggests that cancer-associated somatic ATM mutations are functionally distinct from those in A-T patients. While ~89% of A-T patients carry truncating mutations (frameshift, nonsense, splicing) that abrogate ATM protein expression, ~72% of cancer-associated ATM mutations in TCGA are missense mutations clustering around the kinase domain. Expression of catalytically-inactive ATM protein in hematopoietic stem cells is more oncogenic than loss of ATM, resulting in earlier and more frequent B and T cell lymphomas in mice. Based on these findings, we propose to 1) identify the mechanisms by which catalytically-inactive ATM protein promotes lymphomagenesis beyond loss of ATM; 2) evaluate the consequences of other recurrent ATM missense mutation found in human cancers; and 3) identify agents/targets that can preferentially target ATM-mutated cancers. The results from this study will further elucidate the functions of ATM in DNA repair and tumor suppressionand provide the rationale to selectively target ATM mutated human cancers. ATM missense mutations occur in 4-8% of common epithelial cancers (i.g. colon, bladders, pancreas etc.) in additional to lymphomas and are often associated with poor prognosis. The specific DNA repair defects and selective hypersensitivities identified in this study will provide the basis to target ATM-mutated cancer with selective chemotherapy inclinical trials and lead to new strategies to effectively manage cancer with defects in ATM and other DNA repair genes in the future. The similarity between ATM deficient murine thymic lymphomas and human T-ALL also provide the platform to identify and characterize prognostic markers for human T-ALL.
Our proposed study 1) addresses the molecular mechanisms by which mutated ATM proteins promote lymphomagenesis, 2) identifies novel therapeutic targets for tumors with ATM mutations, and 3) generates novel mouse models to study the role of mutated ATM in lymphomagenesis.
|Roohi, Jasmin; Crowe, Jennifer; Loredan, Denis et al. (2017) New diagnosis of atypical ataxia-telangiectasia in a 17-year-old boy with T-cell acute lymphoblastic leukemia and a novel ATM mutation. J Hum Genet 62:581-584|
|Yamamoto, Kenta; Wang, Jiguang; Sprinzen, Lisa et al. (2016) Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors. Elife 5:|
|Pinkney, Kerice A; Jiang, Wenxia; Lee, Brian J et al. (2015) Haploinsufficiency of Bcl11b suppresses the progression of ATM-deficient T cell lymphomas. J Hematol Oncol 8:94|
|Jiang, Wenxia; Crowe, Jennifer L; Liu, Xiangyu et al. (2015) Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining. Mol Cell 58:172-85|
|Yamamoto, K; Lee, B J; Li, C et al. (2015) Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice. Leukemia 29:1414-24|
|Jiang, Wenxia; Lee, Brian J; Li, Chen et al. (2015) Aberrant TCR? rearrangement underlies the T-cell lymphocytopenia and t(12;14) translocation associated with ATM deficiency. Blood 125:2665-8|
|Avagyan, Serine; Churchill, Michael; Yamamoto, Kenta et al. (2014) Hematopoietic stem cell dysfunction underlies the progressive lymphocytopenia in XLF/Cernunnos deficiency. Blood 124:1622-5|
|Moding, Everett J; Lee, Chang-Lung; Castle, Katherine D et al. (2014) Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium. J Clin Invest 124:3325-38|
|Rass, Emilie; Chandramouly, Gurushankar; Zha, Shan et al. (2013) Ataxia telangiectasia mutated (ATM) is dispensable for endonuclease I-SceI-induced homologous recombination in mouse embryonic stem cells. J Biol Chem 288:7086-95|
|Oksenych, Valentyn; Kumar, Vipul; Liu, Xiangyu et al. (2013) Functional redundancy between the XLF and DNA-PKcs DNA repair factors in V(D)J recombination and nonhomologous DNA end joining. Proc Natl Acad Sci U S A 110:2234-9|
Showing the most recent 10 out of 15 publications